Rockefeller Capital Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Rockefeller Capital Management’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-73	Closed	–	–	4173
2022 Q4	$0	Hold	73	–	–	﹤0.01%	4344
2022 Q3	$0	Sell	73 -154	-68%	-$1.41K	﹤0.01%	4541
2022 Q2	$2K	Hold	227	–	–	﹤0.01%	3877
2022 Q1	$4K	Hold	227	–	–	﹤0.01%	3465
2021 Q4	$8K	Buy	227 +73	+47%	+$4.16K	﹤0.01%	3115
2021 Q3	$11K	Buy	+154	New	+$11.9K	﹤0.01%	2866

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rockefeller Capital Management's SGTX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2023, closing a stake of 73 shares.

Rockefeller Capital Management first reported a position in SGTX in Q3 2021 and held it in 6 quarters. The position peaked at $11K in Q3 2021. 32 funds tracked by Wall St. Rank hold SGTX as of Q1 2023.

Rockefeller Capital Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Rockefeller Capital Management sold 73 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2023.
Rockefeller Capital Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Rockefeller Capital Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $11K in Q3 2021.
32 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.